Pfizer, CFF Focus On Possible Combination Approach To Treating CF’s Underlying Cause
This article was originally published in The Pink Sheet Daily
Executive Summary
Building upon CFTR-focused drugs pioneered by Vertex’s Kalydeco, Pfizer will receive up to $58 million in R&D funding from the Cystic Fibrosis Foundation to bring new CF candidates into the clinic.